BACKGROUND: The exhaled breath of lung cancer patients contains volatile organic compounds (VOCs) that differ from those in healthy individuals. These VOCs can be detected with methods such as ion mobility spectrometry (IMS); their origin remains unknown. METHODS: In 19 patients with lung cancer, exhaled breath was aspirated via the working channel of a flexible bronchoscope from both the tumor-bearing and the opposite lung and analyzed with IMS. RESULTS: IMS measurement through the working channel of a bronchoscope was feasible and safe. In comparison to the opposite lung, we found two peaks that were significantly higher and three peaks that were significantly lower on the IMS of the tumor-bearing site. VOCs differ in concentration depending on the histologic subtype. CONCLUSION: Our results indicate that VOCs in lung cancer patients are produced locally in or around the tumor, and it is most likely that these VOCs represent underlying metabolic processes of the tumor.
BACKGROUND: The exhaled breath of lung cancerpatients contains volatile organic compounds (VOCs) that differ from those in healthy individuals. These VOCs can be detected with methods such as ion mobility spectrometry (IMS); their origin remains unknown. METHODS: In 19 patients with lung cancer, exhaled breath was aspirated via the working channel of a flexible bronchoscope from both the tumor-bearing and the opposite lung and analyzed with IMS. RESULTS: IMS measurement through the working channel of a bronchoscope was feasible and safe. In comparison to the opposite lung, we found two peaks that were significantly higher and three peaks that were significantly lower on the IMS of the tumor-bearing site. VOCs differ in concentration depending on the histologic subtype. CONCLUSION: Our results indicate that VOCs in lung cancerpatients are produced locally in or around the tumor, and it is most likely that these VOCs represent underlying metabolic processes of the tumor.
Authors: Roberto F Machado; Daniel Laskowski; Olivia Deffenderfer; Timothy Burch; Shuo Zheng; Peter J Mazzone; Tarek Mekhail; Constance Jennings; James K Stoller; Jacqueline Pyle; Jennifer Duncan; Raed A Dweik; Serpil C Erzurum Journal: Am J Respir Crit Care Med Date: 2005-03-04 Impact factor: 21.405
Authors: Luis Callol; Francisco Roig; Alfredo Cuevas; Jose Ignacio de Granda; Francisco Villegas; Javier Jareño; Eva Arias; Jose M Albiach Journal: Lung Cancer Date: 2007-02-20 Impact factor: 5.705
Authors: Amel Bajtarevic; Clemens Ager; Martin Pienz; Martin Klieber; Konrad Schwarz; Magdalena Ligor; Tomasz Ligor; Wojciech Filipiak; Hubert Denz; Michael Fiegl; Wolfgang Hilbe; Wolfgang Weiss; Peter Lukas; Herbert Jamnig; Martin Hackl; Alfred Haidenberger; Bogusław Buszewski; Wolfram Miekisch; Jochen Schubert; Anton Amann Journal: BMC Cancer Date: 2009-09-29 Impact factor: 4.430
Authors: Wadah Ibrahim; Michael Wilde; Rebecca Cordell; Dahlia Salman; Dorota Ruszkiewicz; Luke Bryant; Matthew Richardson; Robert C Free; Bo Zhao; Ahmed Yousuf; Christobelle White; Richard Russell; Sheila Jones; Bharti Patel; Asia Awal; Rachael Phillips; Graham Fowkes; Teresa McNally; Clare Foxon; Hetan Bhatt; Rosa Peltrini; Amisha Singapuri; Beverley Hargadon; Toru Suzuki; Leong L Ng; Erol Gaillard; Caroline Beardsmore; Kimuli Ryanna; Hitesh Pandya; Tim Coates; Paul S Monks; Neil Greening; Christopher E Brightling; Paul Thomas; Salman Siddiqui Journal: BMJ Open Date: 2019-03-08 Impact factor: 2.692
Authors: Kaid Darwiche; Paul Zarogoulidis; Leslie Krauss; Filiz Oezkan; Robert Fred Henry Walter; Robert Werner; Dirk Theegarten; Leonidas Sakkas; Antonios Sakkas; Wolfgang Hohenforst-Scmidt; Konstantinos Zarogoulidis; Lutz Freitag Journal: Int J Nanomedicine Date: 2013-11-22